Advertisement

Journal of Inherited Metabolic Disease

, Volume 41, Issue 5, pp 777–784 | Cite as

Medium-chain triglycerides supplement therapy with a low-carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult–onset type II citrullinemia

  • Kiyoshi Hayasaka
  • Chikahiko Numakura
  • Mitsunori Yamakawa
  • Tetsuo Mitsui
  • Hisayoshi Watanabe
  • Hiroaki Haga
  • Masahide Yazaki
  • Hiromasa Ohira
  • Yasuo Ochiai
  • Toshiyuki Tahara
  • Tamio Nakahara
  • Noriyo Yamashiki
  • Takahiro Nakayama
  • Takashi Kon
  • Hiroshi Mitsubuchi
  • Hiroshi Yoshida
Original Article

Abstract

Citrin, encoded by SLC25A13, constitutes the malate-aspartate shuttle, the main NADH-shuttle in the liver. Citrin deficiency causes neonatal intrahepatic cholestasis (NICCD) and adult–onset type II citrullinemia (CTLN2). Citrin deficiency is predicted to impair hepatic glycolysis and de novo lipogenesis, resulting in hepatic energy deficit. Secondary decrease in hepatic argininosuccinate synthetase (ASS1) expression has been considered a cause of hyperammonemia in CTLN2. We previously reported that medium–chain triglyceride (MCT) supplement therapy with a low–carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. We present the therapy for six CTLN2 patients. All the patients’ general condition steadily improved and five patients with hyperammonemic encephalopathy recovered from unconsciousness in a few days. Before the treatment, plasma glutamine levels did not increase over the normal range and rather decreased to lower than the normal range in some patients. The treatment promptly decreased the blood ammonia level, which was accompanied by a decrease in plasma citrulline levels and an increase in plasma glutamine levels. These findings indicated that hyperammonemia was not only caused by the impairment of ureagenesis at ASS1 step, but was also associated with an impairment of glutamine synthetase (GS) ammonia-detoxification system in the hepatocytes. There was no decrease in the GS expressing hepatocytes. MCT supplement with a low–carbohydrate formula can supply the energy and/or substrates for ASS1 and GS, and enhance ammonia detoxification in hepatocytes. Histological improvement in the hepatic steatosis and ASS1-expression was also observed in a patient after long-term treatment.

Abbreviations

NICCD

Neonatal intrahepatic cholestasis

CTLN2

Adult-onset type II citrullinemia

MCT

Medium-chain triglycerides

ASS1

Argininosuccinate synthetase 1

GS

Glutamine synthetase

PSTI

Pancreatic secretory trypsin inhibitor

BMI

Body mass index

γ-GTP

Gamma-glutamyl transpeptidase

ChE

Cholinesterase

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

LDH

Lactate dehydrogenase

LAP

Leucine aminopeptidase

ALP

Alkali phosphatase

CPT

Carbamoyl phosphate transferase

OTC

Ornithine transcarbamylase

CTLN1

Citrullinemia type 1

PPAR

Peroxisome proliferator-activated receptor

Notes

Funding

This work was supported in part by a grant from the Ministry of Health, Labor and Welfare in Japan.

Compliance with ethical standards

Conflicts of interest

K. Hayasaka, C. Numakura, M. Yamakawa, T. Mitsui, H. Watanabe, H. Haga, M. Yazaki, H. Ohira, Y. Ochiai, T. Tahara, T. Nakahara, N. Yamashiki, T. Nakayama, T. Kon, H. Mitsubuchi, and H. Yoshida declare that they have no conflict of interest.

Supplementary material

10545_2018_176_Fig4_ESM.jpg (356 kb)
Suppl. Fig. 1a

Changes in the level of blood ammonia, plasma citrulline, plasma glutamine, and Fischer ratio. (a) blood ammonia, (b) plasma citrulline, (c) glutamine, (d) Fischer ratio. Open circle: case 1, open triangle: case 2, open square: case 3, closed circle: case 4, closed triangle: case 5, closed square: case 6. Normal range is shown by the area within the box (JPEG 356 kb)

10545_2018_176_MOESM1_ESM.eps (366 kb)
High Resolution Image (EPS 365 kb)
10545_2018_176_Fig5_ESM.jpg (357 kb)
Suppl. Fig. 1b

(JPEG 356 kb)

10545_2018_176_MOESM2_ESM.eps (250 kb)
High Resolution Image (EPS 250 kb)
10545_2018_176_Fig6_ESM.jpg (357 kb)
Suppl. Fig. 1c

(JPEG 357 kb)

10545_2018_176_MOESM3_ESM.eps (347 kb)
High Resolution Image (EPS 346 kb)
10545_2018_176_Fig7_ESM.jpg (339 kb)
Suppl. Fig. 1d

(JPEG 339 kb)

10545_2018_176_MOESM4_ESM.eps (283 kb)
High Resolution Image (EPS 282 kb)
10545_2018_176_Fig8_ESM.jpg (1.2 mb)
Suppl. Fig. 2

Immunohistochemical localization of argininosuccinate synthetase 1 (ASS1) in the livers from case 6 before treatment and after treatment. (a) case 6 before treatment (×100), (b) case 6 after about 3 years of treatment (×100). Arrows indicate the patchy areas of ASS1-negative hepatocytes. ASS1-negative hepatocytes were decreased after treatment (JPEG 1277 kb)

10545_2018_176_MOESM5_ESM.eps (21.4 mb)
High Resolution Image (EPS 21926 kb)
10545_2018_176_Fig9_ESM.jpg (337 kb)
Suppl. Fig. 3

(JPEG 337 kb)

10545_2018_176_MOESM6_ESM.eps (159 kb)
High Resolution Image (EPS 159 kb)

References

  1. Bach AC, Babayan VK (1982) Medium-chain triglycerides: an update. Am J Clin Nutr 36:950–962CrossRefPubMedGoogle Scholar
  2. Chakravarthy MV, Pan Z, Zhu Y et al (2005) “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 5:309–322CrossRefGoogle Scholar
  3. Häberle J, Görg B, Rutsch F et al (2005) Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med 353:1926–1933CrossRefPubMedGoogle Scholar
  4. Häussinger D (1983) Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem 133:269–275Google Scholar
  5. Häussinger D, Schliess F (2007) Glutamine metabolism and signaling in the liver. Front Biosci 12:371–391CrossRefPubMedGoogle Scholar
  6. Hayasaka K, Numakura C, Toyota K et al (2012) Treatment with lactose (galactose)-restricted and medium-chain triglyceride-supplemented formula for neonatal intrahepatic cholestasis caused by citrin deficiency. JIMD Rep 2:37–44CrossRefPubMedGoogle Scholar
  7. Hayasaka K, Numakura C, Toyota K et al (2014) Medium-chain triglyceride supplementation under a low-carbohydrate formula is a promising therapy for adult-onset type II citrullinemia. Mol Genet Metab Rep 1:42–50CrossRefPubMedPubMedCentralGoogle Scholar
  8. Kobayashi K, Sinasac DS, Iijima M et al (1999) The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat Genet 22:159–163CrossRefPubMedGoogle Scholar
  9. Komatsu M, Kimura T, Yazaki M et al (2015) Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα. Biochim Biophys Acta 1852:473–481CrossRefPubMedGoogle Scholar
  10. Marten B, Pfeuffer M, Schrezenmeir J (2006) Medium-chain triglycerides. Int Dairy J 16:1374–1382CrossRefGoogle Scholar
  11. Maruyama H, Ogawa M, Nishio T et al (2001) Citrullinemia type II in a 64-year-old man with fluctuating serum citrulline levels. J Neurol Sci 182:167–170CrossRefPubMedGoogle Scholar
  12. Nagasaka H, Okano Y, Tsukahara H et al (2009) Sustaining hypercitrullinemia, hypercholesterolemia and augmented oxidative stress in Japanese children with aspartate/glutamate carrier isoform 2-citrin-deficiency even during the silent period. Mol Genet Metab 97:21–26CrossRefPubMedGoogle Scholar
  13. Qvartskhava N, Lang PA, Görg B et al (2015) Hyperammonemia in gene-targeted mice lacking functional hepatic glutamine synthetase. Proc Natl Acad Sci U S A 112:5521–5526CrossRefPubMedPubMedCentralGoogle Scholar
  14. Saheki T, Song YZ (2017) Citrin deficiency. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews. University of Washington, SeattleGoogle Scholar
  15. Seifter S, Englard S (2009) Energy metabolism. In: Arias I, Wolkoff A, Boyer J et al (eds) The liver: biology and pathobiology, 5th edn. Raven, New York, pp 1–41Google Scholar
  16. Thompson MD, Monga SP (2007) WNT/beta-catenin signaling in liver health and disease. Hepatology 45:1298–1305CrossRefPubMedGoogle Scholar
  17. Uyeda K, Repa JJ (2006) Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4:107–110CrossRefPubMedGoogle Scholar
  18. Wang Y, Viscarra J, Kim SJ (2015) Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol 16:678–689CrossRefPubMedPubMedCentralGoogle Scholar
  19. Wilson CJ, Lee PJ, Leonard JV (2001) Plasma glutamine and ammonia concentrations in ornithine carbamoyltransferase deficiency and citrullinaemia. J Inherit Metab Dis 24:691–695CrossRefPubMedGoogle Scholar
  20. Yasuda T, Yamaguchi N, Kobayashi K et al (2000) Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum Genet 107:537–545CrossRefPubMedGoogle Scholar
  21. Yazaki M, Fukushima K, Saheki T, Ikeda S (2013) Therapeutic strategy for patients with adult onset type II citrullinemia (CTLN2). Program and abstracts for the 3rd Asian Congress for Inherited Metabolic Diseases/the 55th Annual Meeting of the Japanese Society for Inherited Metabolic Diseases, Chiba, p 101Google Scholar

Copyright information

© SSIEM 2018

Authors and Affiliations

  • Kiyoshi Hayasaka
    • 1
    • 2
  • Chikahiko Numakura
    • 1
  • Mitsunori Yamakawa
    • 3
  • Tetsuo Mitsui
    • 1
  • Hisayoshi Watanabe
    • 4
  • Hiroaki Haga
    • 4
  • Masahide Yazaki
    • 5
  • Hiromasa Ohira
    • 6
  • Yasuo Ochiai
    • 7
  • Toshiyuki Tahara
    • 7
  • Tamio Nakahara
    • 8
  • Noriyo Yamashiki
    • 9
  • Takahiro Nakayama
    • 10
  • Takashi Kon
    • 11
  • Hiroshi Mitsubuchi
    • 12
  • Hiroshi Yoshida
    • 13
  1. 1.Department of PediatricsYamagata University School of MedicineYamagataJapan
  2. 2.Department of PediatricsMiyukikai HospitalKaminoyamaJapan
  3. 3.Department of Pathological DiagnosticsYamagata University School of MedicineYamagataJapan
  4. 4.Department of GastroenterologyYamagata University School of MedicineYamagataJapan
  5. 5.Department of Biological Sciences for Intractable Neurological Disorders, Institute for Biomedical SciencesShinshu UniversityNaganoJapan
  6. 6.Department of GastroenterologyFukushima Medical University School of MedicineFukushimaJapan
  7. 7.Department of GastroenterologySaiseikai Utsunomiya HospitalTochigiJapan
  8. 8.Department of GastroenterologyHikone Municipal HospitalHikoneJapan
  9. 9.Organ Transplantation UnitKyoto UniversityKyotoJapan
  10. 10.Division of Internal MedicineNihonkai General HospitalSakataJapan
  11. 11.Department of GastroenterologyYonezawa Municipal HospitalYonezawaJapan
  12. 12.Department of PediatricsGraduate School of Medical Sciences, Kumamoto UniversityKumamotoJapan
  13. 13.Department of PediatricsTsuruoka Municipal Shonai HospitalTsuruokaJapan

Personalised recommendations